BIM
STML

BlackRock Investment Management’s Stemline Therapeutics, Inc. STML Stock Holding History

BlackRock Investment Management’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$790K Sell
73,870
-23
-0% -$278 ﹤0.01% 2835
2016
Q3 		$800K Buy
73,893
+7,800
+12% +$63.4K ﹤0.01% 2807
2016
Q2 		$447K Buy
66,093
+7,676
+13% +$48.5K ﹤0.01% 3116
2016
Q1 		$272K Buy
58,417
+290
+0.5% +$1.42K ﹤0.01% 3098
2015
Q4 		$367K Buy
58,127
+193
+0.3% +$1.57K ﹤0.01% 3106
2015
Q3 		$512K Sell
57,934
-468
-0.8% -$4.91K ﹤0.01% 3013
2015
Q2 		$687K Buy
58,402
+15,264
+35% +$212K ﹤0.01% 3007
2015
Q1 		$624K Buy
43,138
+9,195
+27% +$141K ﹤0.01% 2836
2014
Q4 		$579K Sell
33,943
-115
-0.3% -$1.66K ﹤0.01% 2931
2014
Q3 		$424K Buy
34,058
+769
+2% +$9.46K ﹤0.01% 3056
2014
Q2 		$488K Buy
33,289
+6,426
+24% +$98.5K ﹤0.01% 3055
2014
Q1 		$547K Buy
26,863
+631
+2% +$15.3K ﹤0.01% 2910
2013
Q4 		$514K Buy
26,232
+305
+1% +$8.14K ﹤0.01% 2936
2013
Q3 		$1.17M Buy
25,927
+2,099
+9% +$68.5K ﹤0.01% 2329
2013
Q2 		$568K Buy
+23,828
New +$379K ﹤0.01% 2773

Other funds holding STML

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock Investment Management's STML Position: Q4 2016 in Review

BlackRock Investment Management reduced its Stemline Therapeutics, Inc. (STML) stake by 0.03% in Q4 2016, selling an estimated $278 and leaving 73,870 shares worth $790K. The position accounts for ﹤0.01% of the portfolio, ranked #2835.

BlackRock Investment Management first reported a position in STML in Q2 2013 and has held it in 15 quarters since. The position peaked at $1.17M in Q3 2013. 74 funds tracked by Wall St. Rank hold STML as of Q4 2016.

  • BlackRock Investment Management held 73,870 shares of Stemline Therapeutics, Inc. worth $790K as of Q4 2016.
  • BlackRock Investment Management sold 23 Stemline Therapeutics, Inc. shares in Q4 2016, an estimated $278.
  • Stemline Therapeutics, Inc. made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #2835 holding.
  • BlackRock Investment Management first reported a position in Stemline Therapeutics, Inc. in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Investment Management's Stemline Therapeutics, Inc. position peaked at $1.17M in Q3 2013.
  • 74 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.